Literature DB >> 31517727

FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY (FLIO) PATTERNS IN CLINICALLY UNAFFECTED CHILDREN OF MACULAR TELANGIECTASIA TYPE 2 (MACTEL) PATIENTS.

Lydia Sauer1, Alexandra S Vitale1, Karl M Andersen1,2, Barbara Hart1, Paul S Bernstein1.   

Abstract

PURPOSE: Macular telangiectasia Type 2 (MacTel) is an inherited retinal disease following an autosomal dominant pattern with late onset and reduced penetrance. Fluorescence lifetime imaging ophthalmoscopy (FLIO) enhances diagnosis by showing distinct changes in MacTel. This study investigates FLIO-associated changes in clinically unaffected family members.
METHODS: Eighty-one patients with MacTel (61 ± 12 years), 33 clinically healthy children under age 40 years of these MacTel patients (MacTel-C; 31 ± 6 years), 27 other family members (children over age 40 years, siblings, and parents) and 30 controls were investigated with the Heidelberg FLIO. All subjects underwent multimodal conventional imaging, including optical coherence tomography, blue-light reflectance, fluorescein angiography, and macular pigment imaging.
RESULTS: All 81 patients with MacTel showed typical FLIO patterns. Of the 33 investigated MacTel-C with completely normal eye examinations and conventional imaging, 12 (36%) show FLIO patterns consistent with early MacTel.
CONCLUSION: Prolonged FLIO lifetimes in the parafoveal area within the short spectral channel, especially temporally, are MacTel-specific. Fluorescence lifetime imaging ophthalmoscopy detects these lifetime patterns in over one-third of clinically unaffected MacTel-C. Although further studies will be necessary to determine the specificity of FLIO, it may help diagnose MacTel before conventional imaging modalities show changes or patients experience visual disturbances. Early detection may facilitate future gene discovery studies and interventional trials.

Entities:  

Mesh:

Year:  2020        PMID: 31517727      PMCID: PMC7062574          DOI: 10.1097/IAE.0000000000002646

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   3.975


  36 in total

1.  Monitoring macular pigment changes in macular holes using fluorescence lifetime imaging ophthalmoscopy.

Authors:  Lydia Sauer; Sven Peters; Johanna Schmidt; Dietrich Schweitzer; Matthias Klemm; Lisa Ramm; Regine Augsten; Martin Hammer
Journal:  Acta Ophthalmol       Date:  2016-10-24       Impact factor: 3.761

2.  The prevalence of type 2 idiopathic macular telangiectasia in two African populations.

Authors:  Ferenc B Sallo; Irene Leung; Wanjiku Mathenge; Fatima Kyari; Hannah Kuper; Clare E Gilbert; Alan C Bird; Tunde Peto
Journal:  Ophthalmic Epidemiol       Date:  2012-02-24       Impact factor: 1.648

3.  Imaging of Hydroxychloroquine Toxicity with Fluorescence Lifetime Imaging Ophthalmoscopy.

Authors:  Lydia Sauer; Charles M Calvo; Alexandra S Vitale; Nicholas Henrie; Cole M Milliken; Paul S Bernstein
Journal:  Ophthalmol Retina       Date:  2019-05-02

4.  Autofluorescence Lifetimes in Patients With Choroideremia Identify Photoreceptors in Areas With Retinal Pigment Epithelium Atrophy.

Authors:  Chantal Dysli; Sebastian Wolf; Hoai Viet Tran; Martin S Zinkernagel
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-12-01       Impact factor: 4.799

5.  Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2.

Authors:  Traci E Clemons; Marc C Gillies; Emily Y Chew; Alan C Bird; Tunde Peto; Maria J Figueroa; Molly W Harrington
Journal:  Ophthalmic Epidemiol       Date:  2010 Jan-Feb       Impact factor: 1.648

6.  Fluorescence Lifetime Imaging Ophthalmoscopy: A Novel Way to Assess Macular Telangiectasia Type 2.

Authors:  Lydia Sauer; Rebekah H Gensure; Martin Hammer; Paul S Bernstein
Journal:  Ophthalmol Retina       Date:  2017-12-08

7.  FLIMX: A Software Package to Determine and Analyze the Fluorescence Lifetime in Time-Resolved Fluorescence Data from the Human Eye.

Authors:  Matthias Klemm; Dietrich Schweitzer; Sven Peters; Lydia Sauer; Martin Hammer; Jens Haueisen
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

8.  CNTF Attenuates Vasoproliferative Changes Through Upregulation of SOCS3 in a Mouse-Model of Oxygen-Induced Retinopathy.

Authors:  Felicitas Bucher; Johanna M Walz; Anima Bühler; Edith Aguilar; Clemens Lange; Sophia Diaz-Aguilar; Gottfried Martin; Günther Schlunck; Hansjürgen Agostini; Martin Friedlander; Andreas Stahl
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-08-01       Impact factor: 4.799

9.  Patterns of Fundus Autofluorescence Lifetimes In Eyes of Individuals With Nonexudative Age-Related Macular Degeneration.

Authors:  Lydia Sauer; Rebekah H Gensure; Karl M Andersen; Lukas Kreilkamp; Gregory S Hageman; Martin Hammer; Paul S Bernstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-03-20       Impact factor: 4.799

10.  Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) of Macular Pigment.

Authors:  Lydia Sauer; Karl M Andersen; Binxing Li; Rebekah H Gensure; Martin Hammer; Paul S Bernstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-06-01       Impact factor: 4.799

View more
  3 in total

Review 1.  Fluorescence lifetime imaging ophthalmoscopy: autofluorescence imaging and beyond.

Authors:  Lydia Sauer; Alexandra S Vitale; Natalie K Modersitzki; Paul S Bernstein
Journal:  Eye (Lond)       Date:  2020-12-02       Impact factor: 3.775

2.  Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Patients with Choroideremia.

Authors:  Alexandra S Vitale; Lydia Sauer; Natalie K Modersitzki; Paul S Bernstein
Journal:  Transl Vis Sci Technol       Date:  2020-09-30       Impact factor: 3.283

3.  Autofluorescence Lifetimes Measured with Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) Are Affected by Age, but Not by Pigmentation or Gender.

Authors:  Lydia Sauer; Alexandra S Vitale; Cole M Milliken; Natalie K Modersitzki; J David Blount; Paul S Bernstein
Journal:  Transl Vis Sci Technol       Date:  2020-08-03       Impact factor: 3.283

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.